AmorChem and Bellus Health partner to develop drugs for treating AL amyloidosis
Laval, Québec-based drug development company Bellus Health Inc has partnered with AmorChem, an early-stage life sciences fund managed by Canadian venture capital firm GeneChem, to develop drug candidates for the treatment of AL amyloidosis. As part of the agreement, Bellus will provide proof-of-concept data, know-how and expertise. AmorChem will fund the synthesis to be done at NuChem Therapeutics Inc, and the biological testing. NuChem Therapeutics is a specialty research portfolio company of AmorChem. Bellus is backed by Power Corp's Victoria Square Ventures and other investors.
28 October 2013•5 mins read
